Management of glioblastoma: State of the art and future directions
Glioblastoma is the most common malignant primary brain tumor. Overall, the prognosis for
patients with this disease is poor, with a median survival of< 2 years. There is a slight …
patients with this disease is poor, with a median survival of< 2 years. There is a slight …
Current state of immunotherapy for glioblastoma
M Lim, Y Xia, C Bettegowda, M Weller - Nature reviews Clinical …, 2018 - nature.com
Glioma is the most common primary cancer of the central nervous system, and around 50%
of patients present with the most aggressive form of the disease, glioblastoma. Conventional …
of patients present with the most aggressive form of the disease, glioblastoma. Conventional …
Combination therapy with anti-PD-1, anti-TIM-3, and focal radiation results in regression of murine gliomas
Purpose: Checkpoint molecules like programmed death-1 (PD-1) and T-cell immunoglobulin
mucin-3 (TIM-3) are negative immune regulators that may be upregulated in the setting of …
mucin-3 (TIM-3) are negative immune regulators that may be upregulated in the setting of …
Dendritic cell vaccination of glioblastoma: road to success or dead end
A Datsi, RV Sorg - Frontiers in Immunology, 2021 - frontiersin.org
Glioblastomas (GBM) are the most frequent and aggressive malignant primary brain tumor
and remains a therapeutic challenge: even after multimodal therapy, median survival of …
and remains a therapeutic challenge: even after multimodal therapy, median survival of …
Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy
RM Prins, H Soto, V Konkankit, SK Odesa, A Eskin… - Clinical cancer …, 2011 - AACR
Purpose: To assess the feasibility, safety, and toxicity of autologous tumor lysate–pulsed
dendritic cell (DC) vaccination and toll-like receptor (TLR) agonists in patients with newly …
dendritic cell (DC) vaccination and toll-like receptor (TLR) agonists in patients with newly …
Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell–driven rejection of high-grade glioma
AD Garg, L Vandenberk, C Koks… - Science translational …, 2016 - science.org
The promise of dendritic cell (DC)–based immunotherapy has been established by two
decades of translational research. Of the four malignancies most targeted with clinical DC …
decades of translational research. Of the four malignancies most targeted with clinical DC …
HMGB1 mediates endogenous TLR2 activation and brain tumor regression
Background Glioblastoma multiforme (GBM) is the most aggressive primary brain tumor that
carries a 5-y survival rate of 5%. Attempts at eliciting a clinically relevant anti-GBM immune …
carries a 5-y survival rate of 5%. Attempts at eliciting a clinically relevant anti-GBM immune …
White paper on microbial anti-cancer therapy and prevention
Abstract In this White Paper, we discuss the current state of microbial cancer therapy. This
paper resulted from a meeting ('Microbial Based Cancer Therapy') at the US National …
paper resulted from a meeting ('Microbial Based Cancer Therapy') at the US National …
Immunotherapy advances for glioblastoma
DA Reardon, G Freeman, C Wu, EA Chiocca… - Neuro …, 2014 - academic.oup.com
Survival for patients with glioblastoma, the most common high-grade primary CNS tumor,
remains poor despite multiple therapeutic interventions including intensifying cytotoxic …
remains poor despite multiple therapeutic interventions including intensifying cytotoxic …
Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma
LA Wheeler, AG Manzanera, SD Bell… - Neuro …, 2016 - academic.oup.com
Background Despite aggressive standard of care (SOC) treatment, survival of malignant
gliomas remains very poor. This Phase II, prospective, matched controlled, multicenter trial …
gliomas remains very poor. This Phase II, prospective, matched controlled, multicenter trial …